We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Roche Signs Licensing Agreement with Sysmex Inostics
News

Roche Signs Licensing Agreement with Sysmex Inostics

Roche Signs Licensing Agreement with Sysmex Inostics
News

Roche Signs Licensing Agreement with Sysmex Inostics

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Roche Signs Licensing Agreement with Sysmex Inostics"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Roche announce a licensing agreement with Sysmex Inostics GmbH for its emPCR portfolio of patents. 

Through emulsion PCR (emPCR), each DNA molecule is individually isolated within its own bubble in a water/oil emulsion, which includes a capture bead and PCR amplification reagents. As a result, even though about a million molecules are prepared simultaneously, each molecule is individually amplified to one single bead, the equivalent of having a million separate PCR reactions. This technique allows for massive parallelization (high throughput) that results in a significant cost advantage over Sanger sequencing. Sysmex Inostics GmbH is primarily a clinical service lab providing analysis of free circulating tumor-DNA in plasma for prediction of drug response and for monitoring of cancer by quantifying the amount of tumor DNA to detect relapse and to detect resistance mutations, utilizing emPCR technology. Actual Sysmex Inostics GmbH customers are pharmaceutical companies and academic and medical centers who use Sysmex Inostics services in clinical trials in which tissue collection is a problem.

Dan Zabrowski, Head of Roche Sequencing Unit, said “Roche has an active out-licensing program for its emPCR-based intellectual property portfolio. By continuing to out-license this technology, we contribute to the development of well-validated techniques within the molecular diagnostics field.”

Advertisement